# Vedolizumab

## Entyvio inj 300mg

##### 臨採

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | IENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Indications        | Crohn disease or ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | IVD， ulcerative colitis， Crohn's disease 300 mg at week 0， 2 and 6， followed by every 8 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity reaction， severe or serious， to vedolizumab or any of its excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Gastrointestinal: Nausea (9% ) Musculoskeletal: Arthralgia (12% ) Neurologic: Headache (12% ) Respiratory: Nasopharyngitis (13% )， Upper respiratory infection (7% ) Other: Fatigue (6% )， Fever (9% ) Serious Hepatic: Aminotransferase abnormal， Increased (less than 2% )， Hepatitis， Serum bilirubin raised Immunologic: Anaphylaxis (0.07% )， Hypersensitivity reaction， Infusion reaction (4% ) Neurologic: Progressive multifocal leukoencephalopathy Respiratory: Tuberculosis Other: Cancer (0.4% )， Infectious disease， Sepsis (0.03% ) |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

